Raymond Hohl

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Kuder Craig H; Neighbors Jeffrey D; Hohl Raymond J; Wiemer David F
Synthesis and biological activity of a fluorescent schweinfurthin analogue.
Wiemer Andrew J; Hohl Raymond J; Wiemer David F
The intermediate enzymes of isoprenoid metabolism as anticancer targets.
Miller Antonius A; Murry Daryl J; Owzar Kouros; Hollis Donna R; Kennedy Erin B; Abou-Alfa Ghassan; Desai Apurva; Hwang Jimmy; Villalona-Calero Miguel A; Dees E Claire; Lewis Lionel D; Fakih Marwan G; Edelman Martin J; Millard Fred; Frank Richard C; Hohl Raymond J; Ratain Mark J
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Raymond Hohl (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Kuder Craig H; Neighbors Jeffrey D; Hohl Raymond J; Wiemer David F
Synthesis and biological activity of a fluorescent schweinfurthin analogue.
Bioorganic & medicinal chemistry 2009;17(13):4718-23.
2009: Wiemer Andrew J; Hohl Raymond J; Wiemer David F
The intermediate enzymes of isoprenoid metabolism as anticancer targets.
Anti-cancer agents in medicinal chemistry 2009;9(5):526-42.
2009: Miller Antonius A; Murry Daryl J; Owzar Kouros; Hollis Donna R; Kennedy Erin B; Abou-Alfa Ghassan; Desai Apurva; Hwang Jimmy; Villalona-Calero Miguel A; Dees E Claire; Lewis Lionel D; Fakih Marwan G; Edelman Martin J; Millard Fred; Frank Richard C; Hohl Raymond J; Ratain Mark J
Phase I and pharmacokinetic study of sorafenib in patients with hepatic or renal dysfunction: CALGB 60301.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(11):1800-5.
2009: Holstein Sarah A; Stokes John B; Hohl Raymond J
Renal failure and recovery associated with second-generation Bcr-Abl kinase inhibitors in imatinib-resistant chronic myelogenous leukemia.
Leukemia research 2009;33(2):344-7.
2008: McLennan G; Clarke L; Hohl R J
Imaging as a biomarker for therapy response: cancer as a prototype for the creation of research resources.
Clinical pharmacology and therapeutics 2008;84(4):433-6.
2008: Tong Huaxiang; Wiemer Andrew J; Neighbors Jeffrey D; Hohl Raymond J
Quantitative determination of farnesyl and geranylgeranyl diphosphate levels in mammalian tissue.
Analytical biochemistry 2008;378(2):138-43.
2008: Wiemer Andrew J; Yu Jose S; Shull Larry W; Barney Rocky J; Wasko Brian M; Lamb Kimberly M; Hohl Raymond J; Wiemer David F
Pivaloyloxymethyl-modified isoprenoid bisphosphonates display enhanced inhibition of cellular geranylgeranylation.
Bioorganic & medicinal chemistry 2008;16(7):3652-60.
2008: Dudakovic Amel; Wiemer Andrew J; Lamb Kimberly M; Vonnahme Laura A; Dietz Sara E; Hohl Raymond J
Inhibition of geranylgeranyl diphosphate synthase induces apoptosis through multiple mechanisms and displays synergy with inhibition of other isoprenoid biosynthetic enzymes.
The Journal of pharmacology and experimental therapeutics 2008;324(3):1028-36.
2008: Hamadmad Sumaya N; Hohl Raymond J
Erythropoietin stimulates cancer cell migration and activates RhoA protein through a mitogen-activated protein kinase/extracellular signal-regulated kinase-dependent mechanism.
The Journal of pharmacology and experimental therapeutics 2008;324(3):1227-33.
2008: Wiemer Andrew J; Yu Jose S; Lamb Kimberly M; Hohl Raymond J; Wiemer David F
Mono- and dialkyl isoprenoid bisphosphonates as geranylgeranyl diphosphate synthase inhibitors.
Bioorganic & medicinal chemistry 2008;16(1):390-9.
2007: Hamadmad Sumaya N; Hohl Raymond J
Lovastatin suppresses erythropoietin receptor surface expression through dual inhibition of glycosylation and geranylgeranylation.
Biochemical pharmacology 2007;74(4):590-600.
2007: Miller Antonius A; Murry Daryl J; Owzar Kouros; Hollis Donna R; Lewis Lionel D; Kindler Hedy L; Marshall John L; Villalona-Calero Miguel A; Edelman Martin J; Hohl Raymond J; Lichtman Stuart M; Ratain Mark J
Phase I and pharmacokinetic study of erlotinib for solid tumors in patients with hepatic or renal dysfunction: CALGB 60101.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(21):3055-60.
2007: Widness J A; Schmidt R L; Hohl R J; Goldman F D; Al-Huniti N H; Freise K J; Veng-Pedersen P
Change in erythropoietin pharmacokinetics following hematopoietic transplantation.
Clinical pharmacology and therapeutics 2007;81(6):873-9.
2007: Xing Dezhi; Murry Daryl J; Schmidt Mark S; Hohl Raymond J; Martins James B
Lovastatin specifically prevents focal ischemic ventricular tachycardia due to triggered activity.
Heart rhythm : the official journal of the Heart Rhythm Society 2007;4(5):629-37.
2007: Maalouf Mona A; Wiemer Andrew J; Kuder Craig H; Hohl Raymond J; Wiemer David F
Synthesis of fluorescently tagged isoprenoid bisphosphonates that inhibit protein geranylgeranylation.
Bioorganic & medicinal chemistry 2007;15(5):1959-66.
2007: Mente Nolan R; Wiemer Andrew J; Neighbors Jeffrey D; Beutler John A; Hohl Raymond J; Wiemer David F
Total synthesis of (R,R,R)- and (S,S,S)-schweinfurthin F: differences of bioactivity in the enantiomeric series.
Bioorganic & medicinal chemistry letters 2007;17(4):911-5.
2007: Wiemer Andrew J; Tong Huaxiang; Swanson Kelly M; Hohl Raymond J
Digeranyl bisphosphonate inhibits geranylgeranyl pyrophosphate synthase.
Biochemical and biophysical research communications 2007;353(4):921-5.
2006: Shull Larry W; Wiemer Andrew J; Hohl Raymond J; Wiemer David F
Synthesis and biological activity of isoprenoid bisphosphonates.
Bioorganic & medicinal chemistry 2006;14(12):4130-6.
2006: Swanson Kelly M; Hohl Raymond J
Anti-cancer therapy: targeting the mevalonate pathway.
Current cancer drug targets 2006;6(1):15-37.
2006: Hamadmad Sumaya N; Henry Matthew K; Hohl Raymond J
Erythropoietin receptor signal transduction requires protein geranylgeranylation.
The Journal of pharmacology and experimental therapeutics 2006;316(1):403-9.
2006: Holstein Sarah A; Knapp Howard R; Clamon Gerald H; Murry Daryl J; Hohl Raymond J
Pharmacodynamic effects of high dose lovastatin in subjects with advanced malignancies.
Cancer chemotherapy and pharmacology 2006;57(2):155-64.
2005: Murthy Shubha; Tong Huaxiang; Hohl Raymond J
Regulation of fatty acid synthesis by farnesyl pyrophosphate.
The Journal of biological chemistry 2005;280(51):41793-804.
2005: Lewis Kriste A; Holstein Sarah A; Hohl Raymond J
Lovastatin alters the isoprenoid biosynthetic pathway in acute myelogenous leukemia cells in vivo.
Leukemia research 2005;29(5):527-33.
2005: Tong Huaxiang; Holstein Sarah A; Hohl Raymond J
Simultaneous determination of farnesyl and geranylgeranyl pyrophosphate levels in cultured cells.
Analytical biochemistry 2005;336(1):51-9.
2004: Kim MeeKyoung; Kleckley Troy S; Wiemer Andrew J; Holstein Sarah A; Hohl Raymond J; Wiemer David F
Synthesis and activity of fluorescent isoprenoid pyrophosphate analogues.
The Journal of organic chemistry 2004;69(24):8186-93.
2004: Bailey Howard H; Wilding George; Tutsch Kendra D; Arzoomanian Rhoda Z; Alberti Dona; Feierabend Chris; Simon Kris; Marnocha Rebecca; Holstein Sarah A; Stewart Jan; Lewis Kriste A; Hohl Raymond J
A phase I trial of perillyl alcohol administered four times daily for 14 days out of 28 days.
Cancer chemotherapy and pharmacology 2004;54(4):368-76.
2004: Henry Matthew K; Nimbalkar Dipali; Hohl Raymond J; Quelle Frederick W
Cytokine-induced phosphoinositide 3-kinase activity promotes Cdk2 activation in factor-dependent hematopoietic cells.
Experimental cell research 2004;299(1):257-66.
2004: Burns C Patrick; Halabi Susan; Clamon Gerald; Kaplan Ellen; Hohl Raymond J; Atkins James N; Schwartz Michael A; Wagner Brett A; Paskett Electra
Phase II study of high-dose fish oil capsules for patients with cancer-related cachexia.
Cancer 2004;101(2):370-8.
2004: Veng-Pedersen P; Chapel S; Al-Huniti N H; Schmidt R L; Sedars E M; Hohl R J; Widness J A
Pharmacokinetic tracer kinetics analysis of changes in erythropoietin receptor population in phlebotomy-induced anemia and bone marrow ablation.
Biopharmaceutics & drug disposition 2004;25(4):149-56.
2004: Holstein Sarah A; Hohl Raymond J
Isoprenoids: remarkable diversity of form and function.
Lipids 2004;39(4):293-309.
2003: Veng-Pedersen P; Chapel S; Al-Huniti N H; Schmidt R L; Sedars E M; Hohl R J; Widness J A
A differential pharmacokinetic analysis of the erythropoietin receptor population in newborn and adult sheep.
The Journal of pharmacology and experimental therapeutics 2003;306(2):532-7.
2003: Ownby Susan E; Hohl Raymond J
Isoprenoid alcohols restore protein isoprenylation in a time-dependent manner independent of protein synthesis.
Lipids 2003;38(7):751-9.
2003: Holstein Sarah A; Hohl Raymond J
Monoterpene regulation of Ras and Ras-related protein expression.
Journal of lipid research 2003;44(6):1209-15.
2003: Holstein Sarah A; Wohlford-Lenane Christine L; Wiemer David F; Hohl Raymond J
Isoprenoid pyrophosphate analogues regulate expression of Ras-related proteins.
Biochemistry 2003;42(15):4384-91.
2003: Lee C-K; deMagalhaes-Silverman M; Hohl R J; Hayashi M; Buatti J; Wen B-C; Schlueter A; Strauss R G; Gingrich R D
Donor T-lymphocyte infusion for unrelated allogeneic bone marrow transplantation with CD3+ T-cell-depleted graft.
Bone marrow transplantation 2003;31(2):121-8.
2002: Chen Xuemei; Wiemer Andrew J; Hohl Raymond J; Wiemer David F
Stereoselective synthesis of the 5'-hydroxy-5'-phosphonate derivatives of cytidine and cytosine arabinoside.
The Journal of organic chemistry 2002;67(26):9331-9.
2002: Holstein Sarah A; Wohlford-Lenane Christine L; Hohl Raymond J
Isoprenoids influence expression of Ras and Ras-related proteins.
Biochemistry 2002;41(46):13698-704.
2002: Lee C K; de Magalhaes-Silverman M; Hayashi M; Schlueter A; Strauss R G; Hohl R J; Gingrich R D
A dose escalation study for salvage chemotherapy in patients with refractory lymphoma prior to high-dose myeloablative therapy with stem cell transplantation.
Bone marrow transplantation 2002;29(8):647-52.
2002: Lee C-K; de Magalhaes-Silverman M; Hohl R J; Hayashi M; Buatti J; Wen B C; Schlueter A; Strauss R G; Gingrich R D
Prophylactic T cell infusion after T cell-depleted bone marrow transplantation in patients with refractory lymphoma.
Bone marrow transplantation 2002;29(7):615-20.
2002: Kang Jichao; Kumar Vijay; Yang Dong; Chowdhury Priyanka Roy; Hohl Raymond J
Cyclodextrin complexation: influence on the solubility, stability, and cytotoxicity of camptothecin, an antineoplastic agent.
European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 2002;15(2):163-70.
2002: Holstein Sarah A; Wohlford-Lenane Christine L; Hohl Raymond J
Consequences of mevalonate depletion. Differential transcriptional, translational, and post-translational up-regulation of Ras, Rap1a, RhoA, AND RhoB.
The Journal of biological chemistry 2002;277(12):10678-82.
2002: Ownby Susan E; Hohl Raymond J
Farnesol and geranylgeraniol: prevention and reversion of lovastatin-induced effects in NIH3T3 cells.
Lipids 2002;37(2):185-92.
2001: Holstein S A; Hohl R J
Synergistic interaction of lovastatin and paclitaxel in human cancer cells.
Molecular cancer therapeutics 2001;1(2):141-9.
2001: Chapel S; Veng-Pedersen P; Hohl R J; Schmidt R L; McGuire E M; Widness J A
Changes in erythropoietin pharmacokinetics following busulfan-induced bone marrow ablation in sheep: evidence for bone marrow as a major erythropoietin elimination pathway.
The Journal of pharmacology and experimental therapeutics 2001;298(2):820-4.
2001: Holstein S A; Hohl R J
Interaction of cytosine arabinoside and lovastatin in human leukemia cells.
Leukemia research 2001;25(8):651-60.
2000: Cermak D M; Wiemer D F; Lewis K; Hohl R J
2-(Acyloxy)ethylphosphonate analogues of prenyl pyrophosphates: synthesis and biological characterization.
Bioorganic & medicinal chemistry 2000;8(12):2729-37.
2000: Jung K Y; Hohl R J; Wiemer A J; Wiemer D F
Synthesis of phosphonate derivatives of uridine, cytidine, and cytosine arabinoside.
Bioorganic & medicinal chemistry 2000;8(10):2501-9.
1999: Burns C P; Halabi S; Clamon G H; Hars V; Wagner B A; Hohl R J; Lester E; Kirshner J J; Vinciguerra V; Paskett E
Phase I clinical study of fish oil fatty acid capsules for patients with cancer cachexia: cancer and leukemia group B study 9473.
Clinical cancer research : an official journal of the American Association for Cancer Research 1999;5(12):3942-7.
1999: Gingrich R D; Lee C K; Hohl R; Joyce J; Burns L J; Tamaki K; Wen B C; Scott S
A novel four-drug ablative regimen with hemopoietic stem cell rescue for patients with breast cancer: a phase II study.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1999;5(2):86-93.
1999: Lee C K; Gingrich R D; deMagalhaes-Silverman M; Hohl R J; Joyce J K; Scott S D; Wen B C; Schlueter A
Prophylactic reinfusion of T cells for T cell-depleted allogeneic bone marrow transplantation.
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation 1999;5(1):15-27.
1998: Hohl R J; Sherburne A R; Feeley J E; Huisman T H; Burns C P
Low pulse oximeter-measured hemoglobin oxygen saturations with hemoglobin Cheverly.
American journal of hematology 1998;59(3):181-4.
1998: Holstein S A; Cermak D M; Wiemer D F; Lewis K; Hohl R J
Phosphonate and bisphosphonate analogues of farnesyl pyrophosphate as potential inhibitors of farnesyl protein transferase.
Bioorganic & medicinal chemistry 1998;6(6):687-94.
1998: Hohl R J; Lewis K A; Cermak D M; Wiemer D F
Stereochemistry-dependent inhibition of RAS farnesylation by farnesyl phosphonic acids.
Lipids 1998;33(1):39-46.
1997: Lewis K A; Hohl R J
Modulation of RAS expression in human malignant cells by dietary supplements.
Nutrition (Burbank, Los Angeles County, Calif.) 1997;13(10):921-3.
1996: Goldman F; Hohl R J; Crabtree J; Lewis-Tibesar K; Koretzky G
Lovastatin inhibits T-cell antigen receptor signaling independent of its effects on ras.
Blood 1996;88(12):4611-9.
1996: Lee C K; Harman G S; Hohl R J; Gingrich R D
Fatal cyclophosphamide cardiomyopathy: its clinical course and treatment.
Bone marrow transplantation 1996;18(3):573-7.
1996: Hohl R J
Monoterpenes as regulators of malignant cell proliferation.
Advances in experimental medicine and biology 1996;401():137-46.
1996: Clamon G H; Riggs C E; Dreicer R; Hohl R J
Phase II trial of edatrexate in patients with metastatic colorectal cancer.
Investigational new drugs 1996;13(4):359-61.
1995: Hohl R J; Lewis K
Differential effects of monoterpenes and lovastatin on RAS processing.
The Journal of biological chemistry 1995;270(29):17508-12.
1995: Lee C K; Gingrich R D; Hohl R J; Ajram K A
Engraftment syndrome in autologous bone marrow and peripheral stem cell transplantation.
Bone marrow transplantation 1995;16(1):175-82.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Raymond Hohl

Research Profile (preview)

Chemicals & Drugs

Physiology

Anatomy

Disorders

Genes & Molecular Sequences

Phenomena

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Raymond Hohl (preview)

All Publications